Back to Search
Start Over
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside.
- Source :
-
British Journal of Cancer . 10/14/2014, Vol. 111 Issue 8, p1469-1475. 7p. 1 Chart, 1 Graph. - Publication Year :
- 2014
-
Abstract
- Cancer is a disease caused by DNA mutations. Cancer therapies targeting defined functional mutations have shown clinical benefit. However, as 95% of the mutations in a tumour are unique to that single patient and only a small number of mutations are shared between patients, the addressed medical need is modest. A rapidly determined patient-specific tumour mutation pattern combined with a flexible mutation-targeting drug platform could generate a mutation-targeting individualised therapy, which would benefit each single patient. Next-generation sequencing enables the rapid identification of somatic mutations in individual tumours (the mutanome). Immunoinformatics enables predictions of mutation immunogenicity. Mutation-targeting RNA-based vaccines can be rapidly and affordably synthesised as custom GMP drug products. Integration of these cutting-edge technologies into a clinically applicable process holds the promise of a disruptive innovation benefiting cancer patients. Here, we describe our translation of the individualised RNA-based cancer vaccine concept into clinic trials. [ABSTRACT FROM AUTHOR]
- Subjects :
- *GENETIC translation
*RNA
*CANCER vaccines
*DNA damage
*CLINICAL trials
Subjects
Details
- Language :
- English
- ISSN :
- 00070920
- Volume :
- 111
- Issue :
- 8
- Database :
- Academic Search Index
- Journal :
- British Journal of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 98868277
- Full Text :
- https://doi.org/10.1038/bjc.2013.820